Doximity’s stock skyrockets 50% on medical AI excitement. Can the rally last?
While one analyst thinks Doximity has a compelling AI opportunity, another worries that the company could cannibalize its core business of medical networking.
Wine and Stocks Thoughts about wine and stocks
This mom spent $2,000 on her kindergartner as viral ‘back-to-school hauls’ on TikTok and YouTube spin out of control
Students and parents are breaking their back-to-school budgets thanks to inflation and social-media trends.
Missouri voters just rejected a bid to ditch income tax, while other tax votes loom in Florida and California this fall
Missouri voters rejected a bid to ditch the state’s income tax Tuesday, while big votes loom in Florida and California this fall.
Layoffs fall to the lowest level since the U.S. put men on the moon. Here’s what that says about the economy.
Rising sales and a labor shortage are deterring job cuts. Jobless claims haven’t been this low since 1969.
Should wealthier Americans forgo their Social Security benefits as a charitable gesture?
A reader writes: “I will likely be in a position to decline my benefits.”
3 reasons AMD’s stock is falling in the face of its latest earnings report
Analysts noted that the company delivered muted upside with its results, underwhelmed some investors with its margin outlook and was simply up against high expectations.
3 money rules I swear by — and why they work
Managing money is stressful. The new voice of Don’t Short Yourself is here to share real-life tips and tools we can actually use.
The stock market’s brutal summer reset is finally over. Here is why Citadel Securities says it is time to buy again.
Citadel Securities strategist Scott Rubner said markets have gotten a “technical reset” and is ready to recommend buying stocks again.
Gold is still in its ‘explosive phase,’ says Deutsche Bank, as it sticks to year-end target
Going back as far as 1957 and a few periods notwithstanding, gold tends to outperform CPI and in the last couple of yars this has been especially pronounced.
An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’
AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.
